ERBB2 and breast carcinoma: Of the five intrinsic subtypes, basal-like breast cancer (BLBC) is of particular concern since it does not express estrogen receptor (ER), progesterone receptor (PR), and HER2, and hence does not benefit from anti-estrogenic therapy or trastuzumab 4.